The pharmaceutical giant collapsed by more than 25% during the session following the results of a phase 3 study on Cagrisema, a weight loss drug whose objective was to allow patients to reduce their weight by between 25% and 27%. .
The Danish laboratory has published the main results of REDEFINE 1, a phase III trial which measures the effectiveness and safety at 68 weeks on the subcutaneous administration of CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once daily. week. The trial included 3,417 randomized individuals with obesity or overweight with one or more comorbidities and a mean baseline weight of 106.9 kg.
The trial met its primary endpoint by demonstrating statistically significant and superior weight loss at week 68 with CagriSema compared to placebo. People treated with CagriSema achieved 22.7% greater weight loss after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with the placebo alone. A priori, the buyers surveyed by Jefferies expected on average an absolute weight loss of 25 to 27%.
The Danish index, OMX Copenhagen 20, collapsed by 15%, with Novo Nordisk being by far the largest weighting.
